Transcript Document

The top 15 late-stage blockbusters in the pipeline
Drug
Company
Target
Phase
Therapeutic
Area
2020 sales
NPV
Nivolumab
BMS
Anti-PD-1 mAb
P3
Immuno Onco
6.01
23.1
MK-3475
(pembrolizumab)
Merck
Anti-PD-1 mAb
Filed
Immuno Onco
4.06
16.7
RG7446
Roche
Anti-PD- L1 mAb
P3
Immuno Onco
2.93
15.6
Obeticholic acid
Intercept
FXR agonist
P3
Rare disease
called PBC
2.99
11.4
Ledipasvir/sofosb
uvir
Palbociclib
Gilead
HCV NS5A &
NS5B pol
CDK4/6 inhibitor
Filed
HCV
2.8
9.8
P3
Oncology
2.95
7.9
Cancer vaccine
P3
Oncology
2.04
5.5
DCVax-L
Pfizer
Northwest
Bio
VX-809 +
ivacoftor
MEDI4736
Vertex
CFTR receptor
P3
Cystic fibrosis
1.9
5.0
AstraZeneca
P3
Immuno Onco
0.97
4.7
Lampalizumab
Roche
P2
AMD
1.1
4.5
Evoloumab
LCZ696
Alirocumab
Plegridy
Seculinumab
Amgen
Novartis
Sanofi
Biogen
Novartis
Anti-PD-L1 mAb
Anti-complement
factor D mAb
PCSK9 mAb
ARNI inhibitor
PCSK9 mAb
Interferon beta
Anti-IL17 mAb
P3
P3
P3
Filed
Filed
Cardio
Cardio
Cardio
MS
AIID
1.09
1.3
1.05
1.04
1.03
3.5
3.0
2.9
2.9
2.7
Source: FierceBiotech(http://www.fiercebiotech.com/special-reports/top-15-late-stage-blockbusters-pipeline